ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Long-COVID: A New Name for a Long-Known Symptom Constellation

Gorczynski Reginald Mieczyslaw, Edward John Steele, Wickramasinghe N Chandra, Lindley RA

There has been intense interest in the past 18-24 months on the evolution of a symptom complex in individuals previously infected and/or vaccinated with SARS-CoV-2, which has been described to represent a novel entity, named long-COVID. Included in the symptoms are chronic fatigue, myalgias, depression/anhedonia, poor sleep and in some cases evidence for autoimmune-like responses. The potential drain on medical resources for effective treatment of this condition is enormous, and there is some urgency in developing an improved understanding of the pathophysiology behind it. In the review below we argue that this is unlikely in fact to represent a new entity, but a well-described entity of long-standing (myalgic encephalomyelitis/chronic fatigue syndrome, and fibromyalgia). Even simply pooling the limited data on our understanding of the etiology and treatment of these disorders is likely to improve substantially our ability to deal with the number of individuals presenting with long-COVID, and thus lessen some of the adverse psychological effects associated with “labeling” of this condition.